CTOs on the Move

Immuneering

www.immuneering.com

 
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering`s current development programs in ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Immuneering raised $17M on 12/16/2019
Immuneering raised $20M on 01/22/2020

Similar Companies

Ansa Biotechnologies

Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods.

Mammotome

Mammotome is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Myrexis

Myrexis, Inc. is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ACT Services

ACT Services is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GrayBug

GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.